US FDA Wants To Help Sponsors Generate Evidence CMS Needs, But Won't Be An Intermediary
Executive Summary
FDA-CMS communications are expected to evolve as both agencies look to improve their relationship.
You may also be interested in...
Accelerated Approval Decline? Too Early To Overinterpret US FDA Trend
The US FDA is likely to end 2022 with noticeably fewer Accelerated Approvals granted than in recent years. But it is far too early to conclude that the agency is backing off the pathway – at least in spirit.
US FDA Panel Says Covis’ Makena Should Be Withdrawn – And This Time It Wasn’t Close
Fourteen of 15 advisory committee members said the preterm birth prevention drug should come off the market while a new study is conducted; panelists cited concerns about allowing continued marketing when efficacy has not been demonstrated, and they rejected Covis’ assertion that it would be harder to recruit a new study if Makena were pulled.
‘Industry Failing On Evidence Generation,’ US FDA’s Califf Says Of Accelerated Approvals
As a “laborious” hearing at the Food & Drug Administration on whether to withdraw the accelerated approval for Covis’s pre-term delivery drug Makena, FDA chief Robert Califf commented that industry is not doing enough to provide the evidence required for the fast-track approval pathway.